Episode Details

It's In the News.. a look at the top headlines and stories in the diabetes community. This week's top stories: A new Austrailian study aims to prevent type 1, the new twiist pump will integrate with Eversnse CGM as well as Libre, diabetes deaths are down in the US, Dexcom U is looking for college athletes, and more!

Find out more about Moms' Night Out

Please visit our Sponsors & Partners - they help make the show possible!

Learn more about Gvoke Glucagon Gvoke HypoPen® (glucagon injection): Glucagon Injection For Very Low Blood Sugar (gvokeglucagon.com)

Omnipod - Simplify Life

Learn about Dexcom

Check out VIVI Cap to protect your insulin from extreme temperatures

The best way to keep up with Stacey and the show is by signing up for our weekly newsletter:

Sign up for our newsletter here

Here's where to find us:

Facebook (Group)

Facebook (Page)

Instagram

Twitter

Check out Stacey's books!

Learn more about everything at our home page www.diabetes-connections.com

Reach out with questions or comments: info@diabetes-connections.com

Episode transcription with links:

Hello and welcome to Diabetes Connections In the News! I'm Stacey Simms and every other Friday I bring you a short episode with the top diabetes stories and headlines happening now.

XX

A world-first human trial of a drug designed to treat the underlying cause of type 1 diabetes has begun in Australia.

University of Queensland researcher Ranjeny Thomas said the experimental drug — dubbed ASITI-201 — was designed to retrain the immune system so it no longer attacks the insulin-producing pancreatic cells, known as beta cells.

The drug, given as an injection under the skin, combines fragments of a protein found in the beta cells of people with type 1 diabetes and vitamin D to calm the immune response.

She said if effective, the drug would initially be given to patients with type 1 diabetes as soon as possible after diagnosis to preserve remaining pancreatic cells and reduce the amount of insulin needed.

But eventually, if screening programs can be developed to pick up people at risk of developing type 1 diabetes, it may be possible to "prevent the progression of the disease altogether".

The first in-human trial of 36 participants will test the safety of the drug, but blood tests will also determine the impact of the therapy on a patient's immune system and glucose tolerance.

https://www.abc.net.au/news/2025-04-29/type-1-diabetes-drug-trial-auto-immune-disease-science/105223022

XX